1. Forouzanfar MH, Alexander L, Anderson HR et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 2287–323.
2. Kovesdy CP, L Furth S, Zoccali C; World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. Clin Kidney J 2017; 10 (1): 1–8. DOI: 10.1093/ckj/sfw139. PubMed PMID: 28638599. PubMed Central PMCID: PMC5469573.
3. World Health Organization: Obesity and overweight fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/.
4. Lane M, Zander-Fox DL, Robker RL, McPherson NO. Peri-conception parental obesity, reproductive health, and transgenerational impacts. Trends Endocrinol Metab 2015; 26 (2): 84–90. DOI: 10.1016/j.tem.2014.11.005
5. Ornellas F, Carapeto PV, Mandarim-de-Lacerda CA, Aguila MB. Obese fathers lead to an altered metabolism and obesity in their children in adulthood: review of experimental and human studies. J Pediatr (Rio J) 2017. pii: S0021-7557(16)30437-5. DOI: 10.1016/j.jped.2017.02.004. [Epub ahead of print] Review. PubMed PMID: 28822233.
6. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 2014; 384 (9945): 766–81.
7. Reaven GM. Banting lecture – role of insulin resistance in human disease. Diabetes 1988; 13 (1): 1595–607.
8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–80.
9. Диагностика и лечение метаболического синдрома. Российские рекомендации, третий пересмотр. М., 2013. / Diagnostika i lechenie metabolicheskogo sindroma. Rossiiskie rekomendatsii, tretii peresmotr. M., 2013. [in Russian]
10. Симоненко В.Б., Горюцкий В.Н., Дулин П.А. Роль инсулинорезистентности в патогенезе артериальной гипертонии. Клин. медицина. 2014; 9: 27–33. / Simonenko V.B., Goriutskii V.N., Dulin P.A. Rol' insulinorezistentnosti v patogeneze arterial'noi gipertonii. Klin. meditsina. 2014; 9: 27–33. [in Russian]
11. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23 (11): 1170–8. DOI: 10.1038/ajh.2010.172. PubMed PMID: 20706196.
12. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis 2016; 5: 2048004016633371. DOI: 10.1177/2048004016633371. eCollection 2016 Jan-Dec. Review. PubMed PMID: 26998259; PubMed Central PMCID: PMC4780070.
13. Vaněčková I, Maletínská L, Behuliak M et al. Obesity-related hypertension: possible pathophysiological mechanisms. J Endocrinol 2014; 223 (3): R63–78. DOI: 10.1530/JOE-14-0368. Review. PubMed PMID: 25385879.
14. Nostedt JJ, Switzer NJ, Gill RS et al. The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease. Can J Gastroenterol Hepatol 2016; 2016: 2059245. Published online 2016 Sep 29. DOI: 10.1155/2016/2059245 PMCID: PMC5061986.
15. Quevedo MDP, Palermo M, Serra E, Ackermann MA. Metabolic surgery: gastric bypass for the treatment of type 2 diabetes mellitus. Transl Gastroenterol Hepatol 2017; 2: 58. DOI: 10.21037/tgh.2017.05.10. eCollection 2017. Review. PubMed PMID: 28713862; PubMed Central PMCID: PMC5504088.
16. Buchwald H, Varco R. Metabolic Surgery. New York: Grune & Stratton, 1978.
17. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery. A systematic review and meta-analysis. JAMA 2004; 292: 1724–37.
18. Cefalu WT, Bakris G, Blonde L et al. Standards of Medical Care in Diabetes 2017. Diabetes Care 2017; 40(Suppl. 1): S1–S2. DOI: 10.2337/dc17-S001
19. Sjostrom L, Narbro K, Karason K et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (8): 741–52. DOI: 10.1056/NEJMoa066254
20. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. М., 2017. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. 8-i vyp. M., 2017. [in Russian]
21. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ 2014; 349: g3961.
22. Gletsu-Miller N, Wright BN. Mineral malnutrition following bariatric surgery. Adv Nutr 2013; 4: 506–17. PMID: 24038242. DOI: 10.3945/an.113.004341
23. Красильникова Е.И., Благосклонная Я.В., Быстрова А.А. и др. Адипозопатия – ключевое звено развития состояния инсулинорезистентности. Артериальная гипертензия. 2012; 18 (2): 164–76. / Krasil'nikova E.I., Blagosklonnaia Ia.V., Bystrova A.A. i dr. Adipozopatiia – kliuchevoe zveno razvitiia sostoianiia insulinorezistentnosti. Arterial'naia gipertenziia. 2012; 18 (2): 164–76. [in Russian]
24. Kelley DE, Thaete FL, Troost F. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000; 278: 941–8.
25. Turkoglu C, Duman BS, Gunay D et al. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature. Obes Surg 2003; 13 (5): 699–705.
26. Graßmann S, Wirsching J, Eichelmann F, Aleksandrova K. Association Between Peripheral Adipokines and Inflammation Markers: A Systematic Review and Meta-Analysis. Obesity (Silver Spring) 2017. DOI: 10.1002/oby.21945. [Epub ahead of print] PubMed PMID: 28834421.
27. Свеклина Т.С., Барсуков А.В., Таланцева М.С. Метаболический синдром и воспаление: актуальные вопросы патогенеза. Клин. лаб. диагностика. 2013; 3: 7–10. / Sveklina T.S., Barsukov A.V., Talantseva M.S. Metabolicheskii sindrom i vospalenie: aktual'nye voprosy patogeneza. Klin. lab. diagnostika. 2013; 3: 7–10. [in Russian]
28. Sjostrom L, Lindroos A, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surger. N Eng J Med 2004; 351: 2683–93.
29. IDF taskforce on the epidemiology and prevention, 2011.
30. Heber D, Greenway F, Kaplan L et al. Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010; 95 (11): 4823–43.
31. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 249–61.
32. Rodieux F, Giusti V, D’Alessio D et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008; 16: 298–305.
33. Svane MS, Bojsen-Møller KN, Madsbad S. Medical therapy versus bariatric surgery of obese patients with Type 2 diabetes. Ugeskr Laeger 2016; 178 (44). pii: V06160418. Danish. PubMed PMID: 27808051.
34. Raveendran AV, Shiji PV, Pappachan JM. Role Of Bariatric Surgery In Type 2 Diabetes. BMH Med J 2017; 4 (1): 6–16.
35. DiGiorgi M, Rosen DJ, Choi JJ et al. Re-emergence of diabetes after gastric bypass in patients with mid-to long-term follow-up. Surg Obes Rel Dis 2010; 6: 249–53.
36. Ramos Y et al. Type 2 diabetes reemergence post-gastric bypass surgery, ENDO 2012: Abstract SAT-161.
37. Dimitriadis GK, Randeva MS, Miras AD. Potential Hormone Mechanisms of Bariatric Surgery. Curr Obes Rep 2017. DOI: 10.1007/s13679-017-0276-5. [Epub ahead of print] Review. PubMed PMID: 28780756.
38. Evers SS, Sandoval DA, Seeley RJ. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Ann Rev Physiol 2017; 79: 313–34.
39. Tsoli M, Chronaiou A, Kehagias I et al. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis 2013; 9: 667. DOI: 10.1016/j.soard.2012.12.006
40. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201–29.
41. Pories W, Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis 2009; 5 (2): 285–8.
42. Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709–16.
43. Буеверова Е.Л., Драпкина О.М., Ивашкин В.Т. Атерогенная дислипидемия и печень. Рос. мед. вести. 2008; 13 (1): 17–23. / Bueverova E.L., Drapkina O.M., Ivashkin V.T. Aterogennaia dislipidemiia i pechen'. Ros. med. vesti. 2008; 13 (1): 17–23. [in Russian]
44. Ивашкин В.Т., Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического синдрома. М.: Медицинское информационное агентство, 2012. / Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. M.: Meditsinskoe informatsionnoe agentstvo, 2012. [in Russian]
45. Carswell KA, Belgaumkar AP, Amiel SA, Patel AG. A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg 2016; 26 (4): 843–55.
46. Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010; 21: 329–36.
47. Bechmann LP, Hannivoort RA, Gerken G et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatology 2012; 56 (4): 952–64.
48. Rêgo ADS, Zulin A, Scolari S et al. Analysis of obese patients' medical conditions in the pre and postoperative periods of bariatric surgery. Rev Col Bras Cir 2017; 44 (2): 171–8. DOI: 10.1590/0100-69912017002011. English, Portuguese. PubMed PMID: 28658336.
49. Jamal M, Wegner R, Heitshusen D et al. Resolution of hyperlipidemia follows surgical weight loss in patients undergoing Roux-en-Y gastric bypass surgery a 6-year analysis of data. Surg Obesity Related Dis 2011; 7 (4): 473–9.
50. Silva CF, Cohen L, Sarmento LD et al. Effects of long-term Roux-En-Y gastric bypass on body weight and clinical metabolic comorbidities in bariatric surgery service of a university hospital. Arq Bras Cir Dig 2016; 29 (Suppl. 1): 20–3. DOI: 10.1590/0102-6720201600S10006. English, Portuguese. PubMed PMID: 27683769; PubMed Central PMCID: PMC5064273.
51. Ramos RJ, Mottin CC, Alves LB et al. Effects of size of intestinal diversions in obese patients with metabolic symdrome submitted to gastric bypass. Arq Bras Cir Dig 2016; 29 (Suppl. 1): 15–9. DOI: 10.1590/0102-720201600S10005. English, Portuguese. PubMed PMID: 27683768; PubMed Central PMCID: PMC5064282.
52. Camastra S, Vitali A, Anselmino M et al. Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery. Sci Rep 2017; 7 (1): 9007. DOI: 10.1038/s41598-017-08444-6. PubMed PMID: 28827671; PubMed Central PMCID: PMC5566429.
53. Anderwald CH, Tura A, Promintzer-Schifferl M et al. Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgery. Diabetes Care 2012; 35 (12): 2580–7. DOI: 10.2337/dc12-0197
54. Rubino F, Nathan DM, Eckel RHet al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. Obes Surg 2017; 27: 2. DOI: 10.1007/s11695-016-2457-9
55. Свеклина Т.С. Комплексная клинико-анамнестическая, лабораторно-инструментальная и прогностическая оценка больных артериальной гипертензией в сочетании с сахарным диабетом 2 типа и фибрилляцией предсердий. Дис. ... канд. мед. наук. СПб., 2011. / Sveklina T.S. Kompleksnaia kliniko-anamnesticheskaia, laboratorno-instrumental'naia i prognosticheskaia otsenka bol'nykh arterial'noi gipertenziei v sochetanii s sakharnym diabetom 2 tipa i fibrilliatsiei predserdii. Dis. ... kand. med. nauk. SPb., 2011. [in Russian]
56. Diez J. Altered regulation of the epithelial sodium channel in hypertension. From genes to therapeutics. J Hypertens 2011; 29 (2): 204–6.
57. Корнеева О.Н., Драпкина О.М. Патогенетические взаимосвязи артериальной гипертензии и инсулинорезистентности. Кардиология. 2006; 6: 61–4. / Korneeva O.N., Drapkina O.M. Patogeneticheskie vzaimosviazi arterial'noi gipertenzii i insulinorezistentnosti. Kardiologiia. 2006; 6: 61–4. [in Russian]
58. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulinresistance. Physiol Behav 2008; 94 (2): 206–18.
59. Burns J, Ball SG, Worthy G et al. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens 2012; 30 (10): 2039–46.
60. Govindarajan G. Obesity and hypertension: A clinical update. In: R.Ray, E.Schiffrin, J.R.Sowers, eds. Molecular mechanisms in hypertension. London: Taylor and Francis Pub, 2006; p. 397–406.
61. Wang J, Wang H, Luo W et al. Leptin-induced endothelial dysfunction is mediated by sympathetic nervous system activity. J Am Heart Assoc 2013; 2 (5): e000299.
62. Fernstrom JD, Courcoulas AP, Houck PR, Fernstrom MH. Long-term changes in blood pressure in extremely obese patients who have undergone bariatric surgery. Arch Surg 2006; 141: 276–83.
63. Ahmed AR, Rickards G, Coniglio D et al. Laparoscopic Roux-en-Y Gastric Bypass and Its Early Effect on Blood Pressure. Obes Surg 2008; 19 (7): 845–9.
64. Dallal RM, Hatalski A, Trang A, Chernoff A. Longitudinal analysis of cardiovascular parameters after gastric bypass surgery. Surg Obes Related Dis 2012; 8 (6): 703–9.
65. Hinojosa MW, Varela JE, Smith BR et al. Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 2009; 13 (4): 793–7.
66. Inzucchi SE. Diagnosis of Diabetes. N Engl J Med 2012; 367 (6): 542–50.
67. Zafar MI, Zheng J, Kong W et al. The Role of Vascular Endothelial Growth Factor-B in Metabolic Homeostasis: Current Evidence. Biosci Rep 2017. pii: BSR20171089. DOI: 10.1042/BSR20171089. [Epub ahead of print] PubMed PMID: 28798193.
68. Салухов В.В., Васильев Е.В., Слесарева Е.Г., Гладышев Д.В. Антропометрические показатели пациентов через 4–8 лет после бариатрических оперативных вмешательств. Мед. акад. журн. 2016; 16 (3): 29–31. / Salukhov V.V., Vasil'ev E.V., Slesareva E.G., Gladyshev D.V. Antropometricheskie pokazateli patsientov cherez 4–8 let posle bariatricheskikh operativnykh vmeshatel'stv. Med. akad. zhurn. 2016; 16 (3): 29–31. [in Russian]
69. Loomba R, Abraham M, Unalp A et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56 (3): 943–51.
70. Byrne CD. Dorothy Hodgkin Lecture 2012 Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabetic Medicine 2012; 29: 1098–107.
71. Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications 2013; 27 (3): 293–300.
72. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55 (6): 2005–23.
73. Pillaiand AA, Rinella ME. Nonalcoholic fatty liver disease: is bariatric surgery the answer? Clinics Liv Dis 2009; 13 (4): 689–710.
74. Walenbergh SM, Koek G, Bieqhs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatology 2013; 58 (4): 801–10.
75. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836–46.
76. Dongiovanni P, Valenti L, Rametta R. Genetic variants regulating insulin receptor signaling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease. Gut 2010; 59: 267–73.
77. Bower G, Toma T, Harling L et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg 2015; 25 (12): 2280–9.
78. Alizai PH, Wendl J, Roeth AA et al. Functional liver recovery after bariatric surgery – a Prospective Cohort Study with the LiMAx Test. Obes Surg 2015; 25 (11): 2047–53.
79. Taitano AA, Markow M, Finan JE et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointestinal Surgery 2015; 19 (3): 429–37.
80. Lassailly G, Caiazzo R, Buob D et al. Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149: 377–88.
81. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatology 2016; 64:1388–402. [in Russian]
82. Ghiassi S, Morton J, Bellatorre N, Eisenberg D. Short-term medication cost savings for treating hypertension and diabetes after gastric bypass. Surg Obes Relat Dis 2012; 8 (3): 269–74.

________________________________________________

В.В.Салухов*1, М.С.Блэк1, А.В.Барсуков1, М.А.Харитонов1, Т.С.Свеклина1, Е.В.Васильев2

1 ФГБВОУ ВО «Военно-медицинская академия им. С.М.Кирова» Минобороны России. 194044, Россия, Санкт-Петербург, ул. Академика Лебедева, д. 6;
2 СПб ГБУЗ «Городская больница №40 Курортного района». 197706, Россия, Санкт-Петербург, г. Сестрорецк, ул. Борисова, д. 9
*vlasaluk@yandex.ru

________________________________________________

V.V.Salukhov*1, M.S.Black1, A.V.Barsukov1, M.A.Kharitonov1, T.S.Sveklina1, E.V.Vasiliev2

1 S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation. 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6;
2 City Hospital №40 of Kurortny district. 197706, Russian Federation, Saint Petersburg, g. Sestroretsk, ul. Borisova, d. 9
*vlasaluk@yandex.ru